vs
Amentum Holdings, Inc.（AMTM）与渤健（BIIB）财务数据对比。点击上方公司名可切换其他公司
Amentum Holdings, Inc.的季度营收约是渤健的1.4倍（$3.2B vs $2.3B），Amentum Holdings, Inc.净利率更高（1.4% vs -2.1%，领先3.5%），Amentum Holdings, Inc.同比增速更快（-5.2% vs -7.1%），渤健自由现金流更多（$468.0M vs $-142.0M），过去两年Amentum Holdings, Inc.的营收复合增速更高（25.6% vs -0.2%）
本公司是总部位于美国达拉斯的跨国技术专业服务企业，面向全球企业、机构及政府部门客户提供工程、技术、建设服务以及科学与专项咨询服务，连续6年蝉联《工程新闻纪录》（ENR）全球顶尖设计企业500强榜首。
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
AMTM vs BIIB — 直观对比
营收规模更大
AMTM
是对方的1.4倍
$2.3B
营收增速更快
AMTM
高出1.9%
-7.1%
净利率更高
AMTM
高出3.5%
-2.1%
自由现金流更多
BIIB
多$610.0M
$-142.0M
两年增速更快
AMTM
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.2B | $2.3B |
| 净利润 | $44.0M | $-48.9M |
| 毛利率 | 10.1% | 78.3% |
| 营业利润率 | 4.3% | -2.5% |
| 净利率 | 1.4% | -2.1% |
| 营收同比 | -5.2% | -7.1% |
| 净利润同比 | 266.7% | -118.3% |
| 每股收益（稀释后） | $0.18 | $-0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMTMBIIB
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.9B | $2.3B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | $3.6B | $2.6B | ||
| Q1 25 | $3.5B | $2.4B | ||
| Q4 24 | $3.4B | $2.5B | ||
| Q3 24 | $2.2B | $2.5B | ||
| Q2 24 | $2.1B | $2.5B |
净利润AMTMBIIB
| Q1 26 | $44.0M | — | ||
| Q4 25 | $40.0M | $-48.9M | ||
| Q3 25 | — | $466.5M | ||
| Q2 25 | $10.0M | $634.8M | ||
| Q1 25 | $4.0M | $240.5M | ||
| Q4 24 | $12.0M | $266.7M | ||
| Q3 24 | $26.0M | $388.5M | ||
| Q2 24 | $-26.0M | $583.6M |
毛利率AMTMBIIB
| Q1 26 | 10.1% | — | ||
| Q4 25 | 10.6% | 78.3% | ||
| Q3 25 | — | 73.4% | ||
| Q2 25 | 10.3% | 77.1% | ||
| Q1 25 | 10.5% | 74.1% | ||
| Q4 24 | 10.6% | 76.2% | ||
| Q3 24 | 9.0% | 74.1% | ||
| Q2 24 | 9.6% | 77.8% |
营业利润率AMTMBIIB
| Q1 26 | 4.3% | — | ||
| Q4 25 | 3.4% | -2.5% | ||
| Q3 25 | — | 22.0% | ||
| Q2 25 | 2.9% | 28.1% | ||
| Q1 25 | 3.2% | 12.8% | ||
| Q4 24 | 3.9% | 11.9% | ||
| Q3 24 | 1.2% | 18.3% | ||
| Q2 24 | 4.2% | 28.3% |
净利率AMTMBIIB
| Q1 26 | 1.4% | — | ||
| Q4 25 | 1.0% | -2.1% | ||
| Q3 25 | — | 18.4% | ||
| Q2 25 | 0.3% | 24.0% | ||
| Q1 25 | 0.1% | 9.9% | ||
| Q4 24 | 0.4% | 10.9% | ||
| Q3 24 | 1.2% | 15.8% | ||
| Q2 24 | -1.2% | 23.7% |
每股收益（稀释后）AMTMBIIB
| Q1 26 | $0.18 | — | ||
| Q4 25 | $0.16 | $-0.35 | ||
| Q3 25 | — | $3.17 | ||
| Q2 25 | $0.04 | $4.33 | ||
| Q1 25 | $0.02 | $1.64 | ||
| Q4 24 | $0.05 | $1.82 | ||
| Q3 24 | $0.31 | $2.66 | ||
| Q2 24 | $-0.29 | $4.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $247.0M | — |
| 总债务越低越好 | $3.9B | $6.3B |
| 股东权益账面价值 | $4.6B | $18.3B |
| 总资产 | $11.2B | $29.4B |
| 负债/权益比越低杠杆越低 | 0.86× | 0.34× |
8季度趋势，按日历期对齐
现金及短期投资AMTMBIIB
| Q1 26 | $247.0M | — | ||
| Q4 25 | $437.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $738.0M | — | ||
| Q1 25 | $546.0M | — | ||
| Q4 24 | $522.0M | — | ||
| Q3 24 | $452.0M | — | ||
| Q2 24 | — | — |
总债务AMTMBIIB
| Q1 26 | $3.9B | — | ||
| Q4 25 | $3.9B | $6.3B | ||
| Q3 25 | — | $6.3B | ||
| Q2 25 | $4.5B | $6.3B | ||
| Q1 25 | $4.7B | $4.5B | ||
| Q4 24 | $4.7B | $6.3B | ||
| Q3 24 | $4.7B | $4.5B | ||
| Q2 24 | — | $6.3B |
股东权益AMTMBIIB
| Q1 26 | $4.6B | — | ||
| Q4 25 | $4.5B | $18.3B | ||
| Q3 25 | — | $18.2B | ||
| Q2 25 | $4.5B | $17.6B | ||
| Q1 25 | $4.4B | $17.0B | ||
| Q4 24 | $4.5B | $16.7B | ||
| Q3 24 | $4.5B | $16.4B | ||
| Q2 24 | $303.0M | $15.9B |
总资产AMTMBIIB
| Q1 26 | $11.2B | — | ||
| Q4 25 | $11.5B | $29.4B | ||
| Q3 25 | — | $29.2B | ||
| Q2 25 | $11.8B | $28.3B | ||
| Q1 25 | $12.0B | $28.0B | ||
| Q4 24 | $11.9B | $28.0B | ||
| Q3 24 | $12.0B | $28.3B | ||
| Q2 24 | — | $26.8B |
负债/权益比AMTMBIIB
| Q1 26 | 0.86× | — | ||
| Q4 25 | 0.88× | 0.34× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | 1.01× | 0.36× | ||
| Q1 25 | 1.06× | 0.27× | ||
| Q4 24 | 1.05× | 0.38× | ||
| Q3 24 | 1.05× | 0.28× | ||
| Q2 24 | — | 0.40× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-136.0M | $511.9M |
| 自由现金流经营现金流 - 资本支出 | $-142.0M | $468.0M |
| 自由现金流率自由现金流/营收 | -4.4% | 20.5% |
| 资本支出强度资本支出/营收 | 0.2% | 1.9% |
| 现金转化率经营现金流/净利润 | -3.09× | — |
| 过去12个月自由现金流最近4个季度 | $272.0M | $2.1B |
8季度趋势，按日历期对齐
经营现金流AMTMBIIB
| Q1 26 | $-136.0M | — | ||
| Q4 25 | $270.0M | $511.9M | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $106.0M | $160.9M | ||
| Q1 25 | $57.0M | $259.3M | ||
| Q4 24 | $110.0M | $760.9M | ||
| Q3 24 | — | $935.6M | ||
| Q2 24 | — | $625.8M |
自由现金流AMTMBIIB
| Q1 26 | $-142.0M | — | ||
| Q4 25 | $261.0M | $468.0M | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $100.0M | $134.3M | ||
| Q1 25 | $53.0M | $222.2M | ||
| Q4 24 | $102.0M | $721.6M | ||
| Q3 24 | — | $900.6M | ||
| Q2 24 | — | $592.3M |
自由现金流率AMTMBIIB
| Q1 26 | -4.4% | — | ||
| Q4 25 | 6.6% | 20.5% | ||
| Q3 25 | — | 48.4% | ||
| Q2 25 | 2.8% | 5.1% | ||
| Q1 25 | 1.5% | 9.1% | ||
| Q4 24 | 3.0% | 29.4% | ||
| Q3 24 | — | 36.5% | ||
| Q2 24 | — | 24.0% |
资本支出强度AMTMBIIB
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 1.9% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | 0.2% | 1.0% | ||
| Q1 25 | 0.1% | 1.5% | ||
| Q4 24 | 0.2% | 1.6% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | 1.4% |
现金转化率AMTMBIIB
| Q1 26 | -3.09× | — | ||
| Q4 25 | 6.75× | — | ||
| Q3 25 | — | 2.73× | ||
| Q2 25 | 10.60× | 0.25× | ||
| Q1 25 | 14.25× | 1.08× | ||
| Q4 24 | 9.17× | 2.85× | ||
| Q3 24 | — | 2.41× | ||
| Q2 24 | — | 1.07× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMTM
| Global Engineering Solutions Segment | $1.9B | 59% |
| Other U.S.Government Agencies | $400.0M | 12% |
| Fixed Price Contract | $380.0M | 12% |
| Commercial And International | $226.0M | 7% |
| Time And Materials Contract | $171.0M | 5% |
| Sales Channel Through Intermediary | $78.0M | 2% |
| Equity Method Investee | $50.0M | 2% |
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
